Treatment choice, satisfaction and quality of life in patients with Graves' disease.

Related Articles

Treatment choice, satisfaction and quality of life in patients with Graves' disease.

Clin Endocrinol (Oxf). 2018 Apr 06;:

Authors: Conaglen HM, Tamatea JAU, Conaglen JV, Elston MS

Abstract
Thyrotoxicosis, most often caused by Graves' disease (GD), when treated inadequately may result in premature mortality. There is little consensus as to which of the three treatment options available - antithyroid drugs (ATD), radioactive iodine (RAI) and surgery, is better.
AIMS: 1. To assess factors involved in treatment choice and treatment satisfaction in patients treated for Graves' disease. 2. To assess quality of life (QoL) following treatment of Graves' disease.
METHOD: Participants were selected from a prospective study cohort assessing thyrotoxicosis incidence and severity. Of the 172 eligible patients with Graves' disease, 123 treated patients participated (64% had received ATD only, 11% RAI and 25% total thyroidectomy, the latter two usually after a period of ATD), along with 18 untreated patients with newly diagnosed Graves' disease (overall participation rate 73%). Consented patients completed a questionnaire detailing factors involved in treatment choice, QoL and satisfaction with treatment.
RESULTS: Participants reported that the most important factors in choosing a treatment were: effects on activities of daily living, concern about use of radioiodine, possibility of depression or anxiety, and doctor's recommendations. Satisfaction levels were high across all three treatment types. QoL one year following treatment was higher than in untreated patients, and comparable to other international studies.
CONCLUSIONS: Patient satisfaction with therapy and QoL does not differ by treatment type. Therefore, clinical and social factors, in combination with patient choice and resource availability, should determine which treatment modality patients with Graves' disease should receive. This article is protected by copyright. All rights reserved.

PMID: 29633307 [PubMed - as supplied by publisher]

from Imaging via alkiviadis.1961 on Inoreader https://ift.tt/2JDh1Ml